The July 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 3
Editorial
| Increasing clarity | |
| Yali Friedman |
Commentary
| Personalized medicine and oncology: A commentary and key questions | |
| Robert Freeman |
Articles
| Market access – An essential investment before drug launch | |
| Sean McGrath |
| Rethinking commercial strategy – A patient-centered commercial model | |
| Sanjay K Rao |
| Pathways to biomedical tipping points: Vertical, horizontal or other? | |
| Mark J Ahn, Anne S York, Polly Rizova |
| Key drivers influencing the commercialization of ethanol-based biorefineries | |
| Anuj K Chandel, Om V Singh, Gajula Chandrasekhar, Linga Venkateswar Rao, Mangamoori Lakshmi Narasu |
| Made in India: Are you ready for outsourced contract manufacturing? | |
| Andrew Lees, Sheila Khatri |
Intellectual Property Management
| Controlling costs in patent litigation | |
| Catherine Rajwani |
Legal and Regulatory Updates
| Gene patent considered by English Court of Appeal | |
| Philip Webber |
| Commentary regarding decision in Myriad Genetics on ‘isolated’ DNA claims | |
| Thomas J Kowalski, Deborah L Lu |
Book Reviews
| Book Review: Biotechnology: A Comprehensive Training Guide for the Biotechnology Industry | |
| James Harber |